Clinical Trial Update: A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib in combination with polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory diffuse large B-cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)
• polatuzumab vedotin (polatuzumab vedotin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory or Relapsed Diffuse Large B Cell Lymphoma | Phase 2 | Status: RECRUITING